Novo Nordisk A/S’s Wegovy (semaglutide) and Eli Lilly and Company’s Mounjaro (tirzepatide) are just the start of a promising new obesity market and, while those drugs have demonstrated impressive weight loss, drug developers are already turning their attention to the next generation of obesity medicines and how to address remaining unmet needs.
R&D leaders of companies at the forefront of obesity research discussed some of the next potential frontiers for the metabolic disease area during a panel session at the Galien Forum in New York on 26 October